207(top 1%)
PR articles
15.2K(top 1%)
PR citations
45(top 1%)
PR h-index
48(top 1%)
h-index
227
documents
20.5K
doc citations
1.9K
citing journals
100
times ranked

Publications

219 peer-reviewed articles • 17,814 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts
Cancer Science, 2025, 116, 1034-1047
2.96Citations (PDF)
2REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC
Future Oncology, 2025, 21, 549-556
1.812Citations (PDF)
3Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor
Lung Cancer, 2025, 205, 108631
1.90Citations (PDF)
4HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI
Future Oncology, 2024, 20, 969-980
1.865Citations (PDF)
5Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort
Cancer Research Communications, 2024, 4, 226-235
2.14Citations (PDF)
6Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion
Thoracic Cancer, 2024, 15, 402-409
1.53Citations (PDF)
7Optimal Treatment Strategy for Oligo-Recurrence Lung Cancer Patients with Driver Mutations
Cancers, 2024, 16, 464
2.76Citations (PDF)
8Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
Investigational New Drugs, 2024, 42, 136-144
1.60Citations (PDF)
9Neuroendocrine and squamous cell phenotypes of NUT carcinoma are potential diagnostic pitfalls that discriminating it from mimickers, such as small cell and squamous cell carcinoma
Diagnostic Pathology, 2024, 19, 1-12
1.82Citations (PDF)
10Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers
Thoracic Cancer, 2024, 15, 788-796
1.54Citations (PDF)
11An Exploratory Study of Specimen Processing Methods for Successful Multiplex Genetic Analyses Using Lung Surgical Specimens
Japanese Journal of Lung Cancer, 2024, 64, 11-16
0.10Citations (PDF)
12KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer
Investigational New Drugs, 2024, 42, 261-271
1.64Citations (PDF)
133D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer
Biochemical and Biophysical Research Communications, 2024, 725, 150255
1.53Citations (PDF)
14MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer
Cancer Letters, 2024, 604, 217220
6.73Citations (PDF)
15Association between immune-related adverse events and atezolizumab in previously treated patients with unresectable advanced or recurrent non-small cell lung cancer
Cancer Research Communications, 2024, 4, 2858-2867
2.13Citations (PDF)
16Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
Journal of Clinical Oncology, 2023, 41, 1200-1212
16.5393Citations (PDF)
17Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01)
Thoracic Cancer, 2023, 14, 168-176
1.59Citations (PDF)
18Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer
Cancer Medicine, 2023, 12, 7090-7104
2.08Citations (PDF)
19Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan
Cancer Science, 2023, 114, 2524-2533
2.915Citations (PDF)
20Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients
Investigational New Drugs, 2023, 41, 411-420
1.63Citations (PDF)
21RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
Clinical Lung Cancer, 2023, 24, 415-428
2.124Citations (PDF)
22Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407
Cancer Science, 2023, 114, 3330-3341
2.915Citations (PDF)
23Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial
Cancer Science, 2023, 114, 3698-3707
2.913Citations (PDF)
24First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
International Journal of Clinical Oncology, 2023, 28, 1354-1368
1.611Citations (PDF)
25Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
Translational Lung Cancer Research, 2023, 12, 1702-1716
1.37Citations (PDF)
26Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
Advances in Therapy, 2023, 40, 4545-4560
2.76Citations (PDF)
27Clinical characteristics of patients with KRAS mutation detected by liquid biopsy
Thoracic Cancer, 2023, 14, 3317-3322
1.52Citations (PDF)
28MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF
JCI Insight, 2023
3.711Citations (PDF)
29Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase–rearranged lung adenocarcinoma
Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 441-451.e1
2.013Citations (PDF)
30Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
Cancer Discovery, 2022, 12, 74-89
6.8265Citations (PDF)
31First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Journal of Thoracic Oncology, 2022, 17, 289-308
3.1299Citations (PDF)
32IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Journal of Thoracic Oncology, 2022, 17, 309-323
3.1282Citations (PDF)
33Predictive value of EGFR mutation in non–small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy
Cancer Science, 2022, 113, 287-296
2.919Citations (PDF)
34A Reasonable Definition of Oligo-Recurrence in Non–Small-Cell Lung Cancer
Clinical Lung Cancer, 2022, 23, 82-90
2.116Citations (PDF)
35Relationship Between Pathologic T1 Categories and Pathologic Factors Affecting Prognosis in Pulmonary Adenocarcinoma
JTO Clinical and Research Reports, 2022, 3, 100293
0.62Citations (PDF)
36Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
Journal for ImmunoTherapy of Cancer, 2022, 10, e003027
5.3139Citations (PDF)
37GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
Npj Precision Oncology, 2022, 6, 1-13
5.014Citations (PDF)
38RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
JTO Clinical and Research Reports, 2022, 3, 100303
0.61Citations (PDF)
39Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02)
Thoracic Cancer, 2022, 13, 1471-1478
1.510Citations (PDF)
40Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study
Thoracic Cancer, 2022, 13, 2192-2200
1.59Citations (PDF)
41Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non–small cell lung cancer
Cancer Science, 2022, 113, 3888-3900
2.913Citations (PDF)
42Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors
Targeted Oncology, 2022, 17, 597-604
2.518Citations (PDF)
43Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies
Japanese Journal of Clinical Oncology, 2021, 51, 106-113
1.211Citations (PDF)
44Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
Journal of Thoracic Oncology, 2021, 16, 452-463
3.165Citations (PDF)
45Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
Journal of Thoracic Oncology, 2021, 16, 653-664
3.1434Citations (PDF)
46Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR)
Cancer Science, 2021, 112, 388-396
2.921Citations (PDF)
47Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2
Thoracic Cancer, 2021, 12, 906-913
1.55Citations (PDF)
48Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study
Cancer Science, 2021, 112, 1556-1566
2.919Citations (PDF)
49IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
Cancer Science, 2021, 112, 1534-1544
2.947Citations (PDF)
50Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
Nature Communications, 2021, 12, 1-16
11.096Citations (PDF)
51Outcomes of nodal upstaging comparing video-assisted thoracoscopic surgery versus open thoracotomy for lung cancer.
Lung Cancer, 2021, 152, 78-85
1.913Citations (PDF)
52Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer
Clinical Lung Cancer, 2021, 22, 134-141
2.17Citations (PDF)
53Comparison of local therapy in patients with lung oligo-recurrence of non-small-cell lung cancer
Journal of Surgical Oncology, 2021, 123, 1828-1835
1.29Citations (PDF)
54First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
Journal of Thoracic Oncology, 2021, 16, 665-676
3.143Citations (PDF)
55Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
Npj Precision Oncology, 2021, 5, 1-11
5.028Citations (PDF)
56First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
International Journal of Clinical Oncology, 2021, 26, 1073-1082
1.620Citations (PDF)
57Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients
Anticancer Research, 2021, 41, 2093-2100
0.820Citations (PDF)
58Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib
Cancer Reports, 2021, 4, e1414
1.06Citations (PDF)
59Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer
Lung Cancer, 2021, 155, 40-45
1.921Citations (PDF)
60Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR
Cancer Science, 2021, 112, 2371-2380
2.913Citations (PDF)
61Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non–small-cell lung cancer: KEYNOTE-189 Japan Study
Cancer Science, 2021, 112, 3255-3265
2.957Citations (PDF)
62Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
JTO Clinical and Research Reports, 2021, 2, 100171
0.69Citations (PDF)
63IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
Journal of Thoracic Oncology, 2021, 16, 1909-1924
3.1489Citations (PDF)
64RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer Open Access
Clinical Cancer Research, 2021, 27, 5258-5271
4.538Citations (PDF)
65MO9-1 Real-world data of multiple diagnostic biomarker testing for lung cancer patients in Japan
Annals of Oncology, 2021, 32, S300
19.80Citations (PDF)
66Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
Translational Lung Cancer Research, 2021, 10, 314-325
1.326Citations (PDF)
67Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice
Thoracic Cancer, 2021, 12, 504-511
1.530Citations (PDF)
68Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan
Lung Cancer, 2020, 140, 8-18
1.966Citations (PDF)
69Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
Lung Cancer, 2020, 139, 195-199
1.9138Citations (PDF)
70Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
Journal of Thoracic Oncology, 2020, 15, 609-617
3.138Citations (PDF)
71Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure
Thoracic Cancer, 2020, 11, 3280-3288
1.521Citations (PDF)
72Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY
Cancer Science, 2020, 111, 4510-4525
2.924Citations (PDF)
73Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
Cancer Science, 2020, 111, 3726-3738
2.917Citations (PDF)
745-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study
BMC Pharmacology & Toxicology, 2020, 21, 1-10
2.010Citations (PDF)
75Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR)
ESMO Open, 2020, 5, e000656
3.38Citations (PDF)
76Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases
Thoracic Cancer, 2020, 11, 2465-2472
1.515Citations (PDF)
77Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients
Cancer Treatment and Research Communications, 2020, 25, 100249
1.24Citations (PDF)
78A Novel System to Detect Circulating Tumor Cells Using Two Different Size-selective Microfilters
Anticancer Research, 2020, 40, 5577-5582
0.85Citations (PDF)
79Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
New England Journal of Medicine, 2020, 383, 944-957
24.4912Citations (PDF)
80Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms
Cancer Chemotherapy and Pharmacology, 2020, 86, 517-525
1.33Citations (PDF)
81Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine, 2020, 383, 813-824
24.4762Citations (PDF)
82Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma
Cancer Medicine, 2020, 9, 7418-7427
2.020Citations (PDF)
83Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer
In Vivo, 2020, 34, 2997-3003
0.815Citations (PDF)
84Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment
Lung Cancer, 2020, 144, 71-75
1.936Citations (PDF)
85Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors
BMC Cancer, 2020, 20, 1-8
2.139Citations (PDF)
86Utility of Maximum CT Value in Predicting the Invasiveness of Pure Ground-Glass Nodules
Clinical Lung Cancer, 2020, 21, 281-287
2.133Citations (PDF)
87Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms
Cancer Science, 2020, 111, 932-939
2.949Citations (PDF)
88Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer
Journal of Thoracic Oncology, 2020, 15, 752-765
3.132Citations (PDF)
89Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer
Thoracic Cancer, 2020, 11, 581-587
1.536Citations (PDF)
90Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
Lung Cancer, 2020, 141, 64-71
1.924Citations (PDF)
91Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer
Cancer Science, 2020, 111, 1724-1738
2.930Citations (PDF)
92A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer
Investigational New Drugs, 2020, 38, 1588-1597
1.617Citations (PDF)
93Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer
International Journal of Clinical Oncology, 2020, 26, 507-514
1.61Citations (PDF)
94Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis
Cancer Science, 2019, 110, 2884-2893
2.927Citations (PDF)
95The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Nature Communications, 2019, 10, 1-12
11.0134Citations (PDF)
96Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients
Cancer Science, 2019, 110, 3350-3357
2.910Citations (PDF)
97Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)
Clinical Lung Cancer, 2019, 20, 469-476.e1
2.145Citations (PDF)
98Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer
Journal of Thoracic Disease, 2019, 11, 1919-1928
0.924Citations (PDF)
99Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies
Cancer Medicine, 2019, 8, 5183-5193
2.016Citations (PDF)
100Exploratory analysis of JFCM: Predictive value of rash, EGFR expression, and EGFR copy for necitumumab in squamous NSCLC
Annals of Oncology, 2019, 30, vi109
19.80Citations (PDF)
101Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncology, The, 2019, 20, 1655-1669
14.6569Citations (PDF)
102Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Lancet, The, 2019, 394, 1929-1939
45.92,163Citations (PDF)
103Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
EBioMedicine, 2019, 41, 105-119
6.6124Citations (PDF)
104First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors Free
Molecular Cancer Therapeutics, 2019, 18, 531-540
1.278Citations (PDF)
105Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
European Journal of Cancer, 2019, 116, 137-147
3.5218Citations (PDF)
106Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody
Lung Cancer, 2019, 133, 4-9
1.97Citations (PDF)
107Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
Internal Medicine, 2019, 58, 1479-1484
0.612Citations (PDF)
108Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study
European Journal of Cancer, 2019, 113, 78-86
3.5137Citations (PDF)
109KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small-cell lung cancer
Cancer Science, 2019, 110, 1012-1020
2.950Citations (PDF)
110Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC
International Journal of Clinical Oncology, 2019, 24, 485-493
1.65Citations (PDF)
111Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
Journal of Experimental Medicine, 2019, 216, 982-1000
6.0242Citations (PDF)
112TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
Molecular Cancer Therapeutics, 2019, 18, 920-928
1.213Citations (PDF)
113Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Lancet Respiratory Medicine,the, 2019, 7, 387-401
16.2922Citations (PDF)
114Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995–2017
Lung Cancer, 2019, 131, 69-77
1.942Citations (PDF)
115Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
Investigational New Drugs, 2019, 37, 1207-1217
1.67Citations (PDF)
116Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status
Cancer Research, 2019, 79, 1658-1670
4.2103Citations (PDF)
117Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer
Anticancer Research, 2019, 39, 6851-6857
0.830Citations (PDF)
118Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non–Small-Cell Lung Cancer
Clinical Lung Cancer, 2019, 20, e317-e328
2.134Citations (PDF)
119Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan
Lung Cancer, 2019, 129, 55-62
1.935Citations (PDF)
120Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients
Respiratory Investigation, 2019, 57, 27-33
1.112Citations (PDF)
121Drug interactions between tyrosine kinase inhibitors (gefitinib and erlotinib) and warfarin: Assessment of international normalized ratio elevation characteristics and in vitro CYP2C9 activity
Journal of Oncology Pharmacy Practice, 2019, 25, 1599-1607
0.812Citations (PDF)
122Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC
International Journal of Clinical Oncology, 2019, 25, 67-73
1.610Citations (PDF)
123Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors
Japanese Journal of Clinical Oncology, 2018, 48, 322-328
1.28Citations (PDF)
124High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer
Lung Cancer, 2018, 117, 1-6
1.950Citations (PDF)
125Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
Lung Cancer, 2018, 121, 37-40
1.971Citations (PDF)
126Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing
Cancer Science, 2018, 109, 3921-3933
2.933Citations (PDF)
127First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
New England Journal of Medicine, 2018, 379, 2220-2229
24.43,406Citations (PDF)
128A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L
British Journal of Cancer, 2018, 119, 675-682
4.343Citations (PDF)
129Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment
Journal of Thoracic Oncology, 2018, 13, 915-925
3.129Citations (PDF)
130ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer
Cancer Science, 2018, 109, 2532-2538
2.910Citations (PDF)
131Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9
Cancer Science, 2018, 109, 2863-2872
2.954Citations (PDF)
132EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
Respiratory Medicine Case Reports, 2018, 24, 19-21
0.211Citations (PDF)
133Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations
Cancer Science, 2018, 109, 2852-2862
2.917Citations (PDF)
134Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression
Expert Opinion on Pharmacotherapy, 2018, 19, 1049-1056
1.90Citations (PDF)
135Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer
Clinical Lung Cancer, 2018, 19, 435-440.e1
2.16Citations (PDF)
136EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer
Clinical Lung Cancer, 2017, 18, 527-534.e1
2.1125Citations (PDF)
137Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy
Investigational New Drugs, 2017, 35, 217-226
1.615Citations (PDF)
138Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer
Lung Cancer, 2017, 105, 23-30
1.936Citations (PDF)
139A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis
Scientific Reports, 2017, 7, 1-12
2.7115Citations (PDF)
140Development of indication criteria for preoperative examination in lung cancer.
Asian Cardiovascular and Thoracic Annals, 2017, 25, 281-286
0.40Citations (PDF)
141Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Lancet, The, 2017, 390, 29-39
45.9885Citations (PDF)
142Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer
Cancer Science, 2017, 108, 1000-1006
2.961Citations (PDF)
143Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Lancet Oncology, The, 2017, 18, 874-886
14.6533Citations (PDF)
144Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
Lancet Oncology, The, 2017, 18, 663-671
14.6529Citations (PDF)
145High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases
Pathology International, 2017, 67, 37-44
0.829Citations (PDF)
146JLCS medical practice guidelines for thymic tumors: summary of recommendations.
Japanese Journal of Clinical Oncology, 2017, 47, 1119-1122
1.216Citations (PDF)
147Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study
ESMO Open, 2017, 2, e000214
3.339Citations (PDF)
148Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.
Japanese Journal of Clinical Oncology, 2017, 47, 1189-1192
1.229Citations (PDF)
149Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor
Cancer Medicine, 2017, 6, 2347-2356
2.042Citations (PDF)
150Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy
Supportive Care in Cancer, 2017, 26, 1505-1513
1.56Citations (PDF)
151Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation
Scientific Reports, 2017, 7, 1-12
2.744Citations (PDF)
152Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Lancet Respiratory Medicine,the, 2017, 5, 42-50
16.2281Citations (PDF)
153Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol
Journal of Medical Investigation, 2017, 64, 317-320
0.617Citations (PDF)
154The Efficacy of Ceritinib for ALK-rearranged Non-small Cell Lung Cancer Previously Treated with Alectinib -an Analysis of Japanese and Global Phase I Studies-
Japanese Journal of Lung Cancer, 2017, 57, 175-183
0.10Citations (PDF)
155Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
Drug Safety, 2017, 41, 229-237
2.654Citations (PDF)
156Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting
Anticancer Research, 2017, 37, 1507-1513
0.87Citations (PDF)
157Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy
Anticancer Research, 2017, 37, 4229-4232
0.839Citations (PDF)
158The Current Status of Immunotherapy Using anti PD-1 or PD-L1 Antibodies
Japanese Journal of Lung Cancer, 2017, 57, 75-80
0.10Citations (PDF)
159Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy
Cancer Science, 2016, 107, 1642-1646
2.915Citations (PDF)
160A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
Lung Cancer, 2016, 99, 186-193
1.9109Citations (PDF)
161Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer
Cancer Science, 2016, 107, 315-319
2.98Citations (PDF)
162Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma
Cancer Science, 2016, 107, 320-325
2.923Citations (PDF)
163A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy
Lung Cancer, 2016, 100, 20-23
1.913Citations (PDF)
164A phase II study of carboplatin and pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer
Cancer Treatment and Research Communications, 2016, 9, 100-105
1.21Citations (PDF)
165Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Lancet Oncology, The, 2016, 17, 1643-1652
14.6624Citations (PDF)
166Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
ESMO Open, 2016, 1, e000063
3.339Citations (PDF)
167Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
Lancet Oncology, The, 2016, 17, 1147-1157
14.6146Citations (PDF)
168Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
Lung Cancer, 2016, 93, 43-46
1.953Citations (PDF)
169P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
EBioMedicine, 2016, 3, 54-66
6.6141Citations (PDF)
170Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer
Clinical Lung Cancer, 2016, 17, 24-29.e1
2.12Citations (PDF)
171Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
International Journal of Clinical Oncology, 2016, 22, 70-78
1.611Citations (PDF)
172Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer
Investigational New Drugs, 2016, 35, 37-46
1.632Citations (PDF)
173Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin
Medicine (United States), 2015, 94, e2324
1.041Citations (PDF)
174Significant Prognostic Factors for Completely Resected pN2 Non-small Cell Lung Cancer without Neoadjuvant Therapy
Annals of Thoracic and Cardiovascular Surgery, 2015, 21, 345-353
0.74Citations (PDF)
175Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer
Lung Cancer, 2015, 88, 275-281
1.938Citations (PDF)
176Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors
Journal of Thoracic Oncology, 2015, 10, 1058-1066
3.173Citations (PDF)
177Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer
Investigational New Drugs, 2015, 33, 632-640
1.616Citations (PDF)
178Prognostic value of 18F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer
Cancer Science, 2015, 106, 1554-1560
2.931Citations (PDF)
179Targeting RET Fusion Genes -Translation to Personalized Lung Cancer Therapy-
Japanese Journal of Lung Cancer, 2015, 55, 885-888
0.10Citations (PDF)
180Phase I/II Study of Alectinib (CH5424802/RO5424802) in Patients with ALK-rearranged Non-small Cell Lung Cancer (NSCLC): Updated Results from the AF-001JP Trial
Japanese Journal of Lung Cancer, 2014, 54, 892-897
0.12Citations (PDF)
181A Phase III Study of Cddp, Etop and Irinotecan Vs. Topotecan as 2Nd-Line Chemotherapy for Sensitive Relapsed Sclc: Jcog0605
Annals of Oncology, 2014, 25, v56
19.81Citations (PDF)
182The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer Free
Cancer Discovery, 2014, 4, 662-673
6.8792Citations (PDF)
183Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
Lancet Oncology, The, 2014, 15, 1433-1441
14.6125Citations (PDF)
184Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Lancet Oncology, The, 2014, 15, 1236-1244
14.6738Citations (PDF)
185Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study
Lancet Oncology, The, 2014, 15, 106-113
14.6120Citations (PDF)
186A subset of small cell lung cancer with low neuroendocrine expression and good prognosis: a comparison study of surgical and inoperable cases with biopsy
Human Pathology, 2014, 45, 1045-1056
1.734Citations (PDF)
187Maintenance Chemotherapy for Advanced Non-small Cell Lung Cancer
Japanese Journal of Lung Cancer, 2014, 54, 887-891
0.11Citations (PDF)
188A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)
Lung Cancer, 2013, 82, 109-114
1.992Citations (PDF)
189CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
Lancet Oncology, The, 2013, 14, 590-598
14.6571Citations (PDF)
190Molecular and Clinical Oncology
Molecular and Clinical Oncology, 2013, 1, 263-266
0.94Citations (PDF)
191Abstract A67: Phase I study of HER3 targeted antibody patritumab (U3-1287) in combination with erlotinib in Japanese patients with non-small cell lung cancer (NSCLC).
Molecular Cancer Therapeutics, 2013, 12, A67-A67
1.20Citations (PDF)
192Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma
Journal of Thoracic Oncology, 2011, 6, 1889-1894
3.17Citations (PDF)
193Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer
Cancer Science, 2011, 102, 845-851
2.920Citations (PDF)
194Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study.
Japanese Journal of Clinical Oncology, 2011, 41, 718-22
1.239Citations (PDF)
195A Case of Multiple Cutaneous Metastasis of Lung Cancer to the Finger
Japanese Journal of Lung Cancer, 2011, 51, 243-246
0.10Citations (PDF)
196Prognostic value and significance of subcarinal and superior mediastinal lymph node metastasis in lower lobe tumours.
European Journal of Cardio-thoracic Surgery, 2010, 38, 498-502
1.25Citations (PDF)
197Validity of Omission of Subcarinal Lymph Node Dissection in Patients with Cancer of the Right Upper Lobe Or Left Upper Division of the Lung
Japanese Journal of Lung Cancer, 2008, 48, 266-272
0.14Citations (PDF)
198Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer
Chest, 2007, 131, 1628-1634
0.8106Citations (PDF)
199Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer
Cancer Chemotherapy and Pharmacology, 2007, 61, 503-508
1.317Citations (PDF)
200A Case of Primary Pulmonary Primitive Neuroectodermal Tumor (PNET)
Japanese Journal of Lung Cancer, 2006, 46, 33-39
0.12Citations (PDF)
201Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Japanese Journal of Clinical Oncology, 2006, 36, 547-51
1.26Citations (PDF)
202Postoperative ischemic change in bronchial stumps after primary lung cancer resection.
European Journal of Cardio-thoracic Surgery, 2006, 30, 172-6
1.259Citations (PDF)
203Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer.
Japanese Journal of Clinical Oncology, 2005, 35, 233-8
1.211Citations (PDF)
204Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer
Lung Cancer, 2005, 48, 115-119
1.913Citations (PDF)
205Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy
Lung Cancer, 2005, 49, 245-251
1.923Citations (PDF)
206Serum Levels of KL-6, SP-A and SP-D in NSCLC Patients Treated With Gefitinib
Japanese Journal of Lung Cancer, 2005, 45, 823-828
0.12Citations (PDF)
207Rapid induction of tumor necrosis factor cytotoxicity in naive splenic T cells by simultaneous CD80 (B7.1) and CD54 (ICAM-1) co-stimulation
European Journal of Immunology, 1996, 26, 2160-2164
2.46Citations (PDF)
208Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies
Lung Cancer, 0, 209, 108793
1.90Citations (PDF)
209Tumor heterogeneity involving SCLC with a single exon deletion in RB1 and adenocarcinoma with EGFR-L718V mutation in EGFR-TKI–resistant lung cancer
Lung Cancer, 0, 210, 108833
1.91Citations (PDF)
210Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2)
Cancer Science, 0, 117, 727-738
2.92Citations (PDF)
211Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results.
JTO Clinical and Research Reports, 0, 7, 100962
0.60Citations (PDF)
212Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52
Cancer Science, 0, 117, 1124-1135
2.91Citations (PDF)
213Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study).
JTO Clinical and Research Reports, 0, 7, 100963
0.60Citations (PDF)
214Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab
Cancer Science, 0, 117, 904-916
2.91Citations (PDF)
215Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.
Cancer Science, 0, 117, 1948-1960
2.91Citations (PDF)
216Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.
Cancer Science, 0, 117, 1935-1947
2.90Citations (PDF)
217Effect of prior chemotherapy on survival in patients from the randomized phase III J-ALEX study of alectinib versus crizotinib in ALK-positive non-small cell lung cancer
0, 1, 100050
0Citations (PDF)
218Real-world profile and clinical impact of central nervous system adverse events in patients with ALK-positive NSCLC treated with first-line lorlatinib in Japan: The first interim analysis from the ROYAL study
0, 1, 100054
0Citations (PDF)
219Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis.
International Journal of Clinical Oncology, 0
1.60Citations (PDF)